Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Ovarian Neoplasms

  Free Subscription


1 Clin Cancer Res
3 Gynecol Oncol
1 Int J Cancer
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Clin Cancer Res

  1. TIAN L, Xu B, Teng KY, Song M, et al
    Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1248.
    PubMed         Abstract available

    Gynecol Oncol

  2. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    PubMed         Abstract available

  3. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.

  4. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    PubMed         Abstract available

    Int J Cancer

  5. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    PubMed         Abstract available

    PLoS One

  6. HO PJ, Yeoh YS, Miao H, Lim SH, et al
    Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
    PLoS One. 2021;16:e0250102.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.